Literature DB >> 11282201

Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.

L Haan1, W R Verweij, M Holtrop, R Brands, G J van Scharrenburg, A M Palache, E Agsteribbe, J Wilschut.   

Abstract

Local mucosal IgA antibodies play a central role in protection of the respiratory tract against influenza virus infection. Therefore, new-generation influenza vaccines should aim at stimulating not only systemic, but also local antibody responses. Previously, we demonstrated that the recombinant B subunit of the Escherichia coli heat-labile toxin (LTB) is a potent adjuvant towards nasally administered influenza subunit antigen. Here, we investigated the protection conferred by LTB-supplemented influenza subunit antigen given intranasally (i.n.) or intramuscularly (i.m.) to mice. Both i.n. and i.m. immunization with subunit antigen and LTB completely protected the animals against viral infection. Protection upon i.n. immunization was associated with the induction of antigen-specific serum IgG and mucosal IgA, whereas protection upon i.m. immunization correlated with strong serum and mucosal IgG, but not IgA responses. We conclude that LTB-supplemented influenza subunit antigen, given either i.n. or i.m, induces protective antibody-mediated mucosal immunity and thus represents a promising novel flu vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282201     DOI: 10.1016/s0264-410x(00)00556-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1.

Authors:  Zhisheng Wang; Qinghua Yu; Junkai Gao; Qian Yang
Journal:  Clin Vaccine Immunol       Date:  2011-11-30

2.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

3.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

4.  Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats.

Authors:  M Pravetoni; D E Keyler; M D Raleigh; A C Harris; M G Lesage; C K Mattson; S Pettersson; P R Pentel
Journal:  Biochem Pharmacol       Date:  2011-02-17       Impact factor: 5.858

Review 5.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

6.  Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.

Authors:  Yossef Raviv; Robert Blumenthal; S Mark Tompkins; Jennifer Humberd; Robert J Hogan; Mathias Viard
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

Review 7.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

8.  The immune response induced by DNA vaccine expressing nfa1 gene against Naegleria fowleri.

Authors:  Jong-Hyun Kim; Sang-Hee Lee; Hae-Jin Sohn; Jinyoung Lee; Yong-Joon Chwae; Sun Park; Kyongmin Kim; Ho-Joon Shin
Journal:  Parasitol Res       Date:  2012-09-07       Impact factor: 2.289

9.  Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route.

Authors:  Guo-guang Zhang; Dong-xiao Li; Hui-huang Zhang; Ya-ming Zeng; Liang Chen
Journal:  Vet Res Commun       Date:  2009-05-22       Impact factor: 2.459

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.